CD27 and neoplasm: In a recent study, a library of CAR-T cell constructs with several co-stimulatory domains was evaluated, with the combination of CD27 and DAP-10 yielding the best anti-tumor response in vitro against 24JK erbB2-positive sarcoma cells as well as in vivo in NOD-SCID mice [81].